Puma Biotechnology’s (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings

Investors were disappointed with the weak earnings posted by Puma Biotechnology, Inc. (NASDAQ:PBYI ). Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Zooming In On Puma Biotechnology’s Earnings

Many investors haven’t heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company’s profit is backed up by free cash flow (FCF) during a given period. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company’s average operating assets over that period. You could think of the accrual ratio from cashflow as the ‘non-FCF profit ratio’.

That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While having an accrual ratio above zero is of little concern, we do think it’s worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, “firms with higher accruals tend to be less profitable in the future”.

Over the twelve months to March 2026, Puma Biotechnology recorded an accrual ratio of -0.60. Therefore, its statutory earnings were very significantly less than its free cashflow. Indeed, in the last twelve months it reported free cash flow of US$54m, well over the US$24.4m it reported in profit. Puma Biotechnology’s free cash flow improved over the last year, which is generally good to see.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Puma Biotechnology’s Profit Performance

As we discussed above, Puma Biotechnology’s accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Because of this, we think Puma Biotechnology’s underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! And on top of that, its earnings per share have grown at an extremely impressive rate over the last three years. At the end of the day, it’s essential to consider more than just the factors above, if you want to understand the company properly. So if you’d like to dive deeper into this stock, it’s crucial to consider any risks it’s facing. To help with this, we’ve discovered 2 warning signs (1 makes us a bit uncomfortable!) that you ought to be aware of before buying any shares in Puma Biotechnology.

This note has only looked at a single factor that sheds light on the nature of Puma Biotechnology’s profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.